This clinical trial is focused on studying a condition known as Multiple System Atrophy (MSA), a rare neurological disorder that affects the body’s involuntary functions, such as blood pressure, breathing, and motor control. The study will evaluate a new treatment called Emrusolmin, which is also known by its code name TEV-56286. This medication is taken orally in the form of a capsule. The trial will compare the effects of Emrusolmin with a placebo to understand its effectiveness in treating MSA.
The purpose of the study is to assess how well Emrusolmin works in improving the symptoms of MSA. Participants in the study will be randomly assigned to receive either Emrusolmin or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This approach helps ensure that the results are unbiased. The study will last for a period of 48 weeks, during which participants will be monitored regularly to track any changes in their condition and to ensure their safety.
Throughout the study, various assessments will be conducted to evaluate the impact of the treatment on the participants’ symptoms and overall quality of life. These assessments will include standardized tests and questionnaires that measure the severity of MSA symptoms and the participants’ well-being. The study aims to provide valuable information about the potential benefits of Emrusolmin for individuals living with Multiple System Atrophy.
France 
Germany 
Italy 
Spain